Monoclonal antibody lenzilumab boosts survival in COVID hospital patientsThe neutralizing monoclonal antibody lenzilumab significantly raised survival without the use of mechanical ventilation in hospitalized COVID-19 patients and had a good safety profile, according to a phase 3 clinical trial yesterday in The Lancet Respiratory Medicine.A team led by Mayo Clinic researchers enrolled 520 hospitalized COVID-19 pneumonia patients from 29 sites in the United States and Brazil from May 5, 2020, to Jan 27, 2021; 479 patients were included in a modified intention-to-treat population.
Participants were randomly assigned in a 1:1 ratio to receive either three intravenous 600-milligram (mg) doses of lenzilumab or a placebo given 8 hours apart.Avera